SOURCE: PURE Bioscience, Inc.

PURE Bioscience, Inc.

June 03, 2015 16:03 ET

PURE Bioscience Prepares to Resubmit Food Contact Notification With FDA for SDC Antimicrobial Use in Raw Poultry Processing

SAN DIEGO, CA--(Marketwired - Jun 3, 2015) - PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that as a result of recent discussions with the FDA, PURE intends to resubmit its Food Contact Notification (FCN) for use of its SDC antimicrobial in raw poultry processing before the end of June.

SDC test results demonstrate materially significant reduction of Salmonella contamination in poultry. The data indicates that the use of an SDC antimicrobial solution in poultry processing has the potential to enable plants to achieve non-detectable Salmonella levels after the chilling process.

Management intends to provide additional information about the re-submission, including a discussion of timing and the approval process, during its fiscal Q3 results conference call next week.

Hank R. Lambert, CEO, said, "The results of recent testing indicate a significant reduction of silver residues on poultry treated with SDC to nearly non-detectable levels. We believe this data adequately addresses the FDA's prior issues. We look forward to the completion of the regulatory review process in order to bring SDC to market as an effective intervention component of an integrated food safety system for poultry processing."

About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at http://www.purebio.com/

Forward-looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's cash position and liquidity requirements; the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including acceptance of the Company's PURE Hard Surface disinfectant by SUBWAY® franchisees; and the ability to convert successful evaluations into customer orders; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw poultry processing; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including Forms 10-Q and 10-K. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. 

Contact Information

  • Contacts:
    Peter C. Wulff
    CFO & COO
    PURE Bioscience, Inc.
    619-596-8600 ext.111
    Email Contact

    Terri MacInnis
    VP of IR
    Bibicoff + MacInnis, Inc.
    818-379-8500
    Email Contact

    Tom Hemingway
    Redwood Investment Group
    714-978-4425
    Email Contact